CMV INFECTIONS IN AIDS PATIENTS ON ANTI-VIRAL CLINICAL PROTOCOLS

接受抗病毒临床治疗的艾滋病患者的巨细胞病毒感染

• 批准号: 3748150
• 负责人: J F MANISCHEWITZ
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3748150
• 关键词: AIDS therapy; Herpesviridae disease; adenine analog; antiAIDS agent; antiviral antibody; blood tests; clinical trials; combination chemotherapy; communicable disease control; cytomegalovirus; cytosine analog; diagnostic respiratory lavage; helper T lymphocyte; human subject; human therapy evaluation; immunoglobulins; immunotherapy; interferon alpha; interleukin 2; microorganism disease chemotherapy; opportunistic infections; urinalysis; zidovudine

(1) Goals of Project: Since CMV is recognized as one of the leading opportunistic infections in AIDS patients, it is important to monitor blood, urine, and tissue specimens from patients enrolled in various clinical trials for the presence of CMV. (2) Subjects of Clinical Protocols: (a) Combination therapies against HIV-1 : AZT/IL2, IFN-alpha /IL2, and a three arm trial of combination AZT, IFN, and AZT/IFN. (b) A randomized double blind trial to determine the efficacy of CMV-IG as prophylaxis for CMV infections in AIDS patients. (c) Phase I trial with a Cytosine derivative (HPMPC) for the prevention and/or treatment of CMV infections in AIDS patients. (d) Phase I trial of an Adenine analog (PMEA) as a potential drug with dual anti- viral effects on HIV-1 and Herpes viruses. (patient population: AIDS with CD4 < 200). (e) Another goal of this project is to determine if CMV can be isolated from bronchial lavage specimens taken from asymptomatic as well as symptomatic HIV-1 patients. It may provide an early indicator of reactivated CMV in these patients, and lead to early initiation of anti-CMV treatment to prevent systemic fulminating disease. (3) Major Findings: Most Trials are ongoing. Preliminary results from trial (a) suggest that CMV-IG did not decrease CMV viruria in treated patients and may not be beneficial as a prophylactic agent.

(1) 项目目标：由于 CMV 被认为是领先的 艾滋病患者机会性感染，监测很重要 血液、尿液和组织样本均来自于不同研究项目的患者 CMV 存在的临床试验。 (二)临床科目 方案： (a) 针对 HIV-1 的联合疗法：AZT/IL2、IFN-α /IL2，以及 AZT、IFN 和 AZT/IFN 组合的三臂试验。 (二) 一项随机双盲试验，以确定 CMV-IG 的功效 艾滋病患者巨细胞病毒感染的预防。 (c) 第一阶段试验 用于预防和/或治疗 CMV 的胞嘧啶衍生物 (HPMPC) 艾滋病患者的感染。 (d) 腺嘌呤类似物的 I 期试验 (PMEA)作为一种潜在药物，对HIV-1和HIV-1具有双重抗病毒作用 疱疹病毒。 （患者人群：CD4 < 200 的 AIDS）。 (e) 另一个 该项目的目标是确定是否可以将 CMV 与 支气管灌洗标本取自无症状和有症状的患者 HIV-1 患者。它可以提供 CMV 重新激活的早期指标 这些患者，并导致早期开始抗 CMV 治疗 预防全身性暴发性疾病。 (3) 主要发现：大多数试验 正在进行中。试验 (a) 的初步结果表明 CMV-IG 确实 不会减少接受治疗的患者的巨细胞病毒病毒尿，并且可能没有益处 作为预防剂。